摘要
目的 探讨脉管复康片对动脉粥样硬化性心血管疾病（ASCVD）患者血脂、动脉粥样硬化程度、炎症因子的影响。方法 选取6个中心82例ASCVD患者，按照随机数字表法分为试验组39例和对照组43例，对照组予阿司匹林肠溶片抗小板、阿托伐他汀钙片调脂的标准治疗，试验组在此基础上联合脉管复康片治疗，观察周期均为48周，比较两组患者治疗前后血清甘油三酯（TG）、胆固醇（TC）、低密度脂蛋白-C（LDL-C）、高密度脂蛋白-C（HDL-C）、颈动脉内膜中层厚度（IMT）、颈动脉斑块（Crouse）评分变化以及炎症因子血清超敏C反应蛋白（hs-CRP ）、单核细胞趋化蛋白-1（MCP-1）、巨噬细胞移动抑制因子（MIF）、肿瘤坏死因子-ɑ（TNF-ɑ）、细胞黏附分子-1（VCAM-1）、基质金属蛋白酶-9（MMP-9）、白细胞介素-1β（IL-1β）水平变化。结果 治疗后试验组IMT及Crouse评分均显著低于治疗前（P＜0.01）；TG、TC、LDL-C、HDL-C两组比较无明显差异；hs-CRP、MCP-1、MIF、TNF-ɑ、VCAM-1、MMP-9、IL-1β水平均较治疗前下降，且治疗后试验组患者各指标水平均明显低于对照组（P＜0.01）。结论 脉管复康片可显著抑制ASCVD患者炎症因子表达，保护血管内皮细胞及稳定、延缓粥样硬化斑块发生、发展。
关键词： 脉管复康片；ASCVD；IMT；Crouse评分；炎症因子
Abstract
Objective To investigate the effects of Maiguanfukang tablet on blood lipid, atherosclerosis degree and inflammatory factors in patients with atherosclerotic cardiovascular disease (ASCVD). Methods A total of 82 patients with ASCVD from 6 centers were selected and divided into experimental group (39 cases) and control group (43 cases) according to random number table method. The control group received standard treatment of aspirin enteric-coated tablets and atorvastatin calcium tablets for lipid regulation, and the experimental group received combined treatment with Maiguangfukang tablets on this basis. The observation period was 48 weeks. Serum triglyceride (TG), cholesterol (TC), low density lipoprotein C (LDL-C), high density lipoprotein C (HDL-C), carotid intimax-media thickness (IMT), carotid plaque (Crouse) score and the inflammatory factor serum hypersensitive C-reactive protein (hs-CRP) were compared between the two groups before and after treatment ), monocyte chemoattractant protein-1 (MCP-1), macrophage migration inhibitor factor (MIF), tumor necrosis factor-alpha (TNF-alpha), cell adhesion molecule-1 (VCAM-1), matrix metalloproteinase-9 (MMP-9), interleukin-1β (IL-1β) levels changed. Results IMT and Crouse scores were significantly lower after treatment than before treatment (P < 0.01). There was no significant difference between TG, TC, LDL-C and HDL-C groups. The levels of hs-CRP, MCP-1, MIF, TNF-alpha, VCAM-1, MMP-9 and IL-1β were all decreased compared with those before treatment, and the levels of all indexes in experimental group were significantly lower than those in control group after treatment (P < 0.01). Conclusion Maaiguanfukang tablet can significantly inhibit the expression of inflammatory factors in ASCVD patients, protect vascular endothelial cells, stabilize and delay the occurrence and development of atherosclerotic plaques.
Key words： Mai Guan Fukang tablet; ASCVD; IMT; Crouse score; Inflammatory factor
参考文献 References
[1] 国家心血管病中心.中国心血管健康与疾病报告2021[M]. 北京:科学出版社,2022.
[2] 中国心血管健康与疾病报告2020概要[J].中国循环杂志,2021(06vo36):521-545.
[3] Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and mta-analysis[J]. JAMA,2018,319 (15): 1566-1579.
[4] Kapoor D, Vijayvergiya R, et al. Conventional therapies fail to target inflammation and immune imbalance in subjects with stable coronary artery disease: a system-based approach[J/OL]. Atherosclerosis,2014,237(2):623-631.
[5] 中国血脂管理指南修订联合专家委员会.中国血脂管理指南（2023年).中国循环杂志,2023,38(3):237-271.
[6] Barrett T J. Macrophages in Atherosclerosis Regression[J/OL]. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020,40(1):20-33.
[7] Bigeh A, Sanchez A, Maestas C,et al. Inflammatory bowel disease and the risk for cardiovascular disease: Does all inflammation lead to heart disease?[J/OL]. Trends in Cardiovascular Medicine, 2020,30(8):463-469.
[8] Zhu Y, Xian X, Wang Z, et al. Research Progress on the Relationship between Atherosclerosis and Inflammation [J/OL]. Biomolecules,2018,8(3):80.
[9] Wang H, Chen Y, Liu X, et al. TNF-αderived from arsenite-induced microglia activation mediated neuronal necroptosis[J/OL]. Ecotoxicology and Environmental Safety, 2022, 236: 113468.
[10] 刘楠. 阿司匹林联合氯吡格雷双抗血小板治疗脑梗死的疗效观察及对血清hs-CRP及D-D水平的影响[J].医学信息,2022,35(19):82-84.
[11] 周国锐,岳姣姣,朱涛,等.通络化痰汤联合依达拉奉治疗脑梗死后血管性认知障碍患者的临床疗效及对其认知功能及血清hs-CRP、TNF-α水平的影响[J/OL].世界中西医结合杂志,2022,17(9): 1886-1890+1908.
[12] Fu W, Chen M, Ou L, et al. Xiaoyaosan prevents atherosclerotic vulnerable plaque formation through heat shock protein/glucocorticoid receptor axis-mediated mechanism[J]. American Journal of Translational Research, 2019, 11(9):5531-5545.
[13] Holm Nielsen S, Jonasson L, Kalogeropoulos K, et al. Exploring the role of extracellular matrix proteins to develop biomarkers of plaque vulnerability and outcome[J/OL].Journal of Internal Medicine,2020, 287(5): 493-513.
[14] 孙莹心,韩萍,王新陆.基于血浊理论探讨动脉粥样硬化前期病变的中医辨证施治[J].天津中医药, 2021,38(12): 1544-1547.
[15] 段盈竹,张欢,于游,等.基于“木郁土壅”理论从“肝-肠轴学说”探析越鞠丸防治动脉粥样硬化的机制[J/OL].中华中医药学刊, 2022,40(10):99-102.
[16] 李帅帅, 于红红, 田维毅. 中医药通过调节microRNAs干预动脉粥样硬化研究进展[J]. 时珍国医国药, 2021, 32(8): 1968-1971.
[17] Rosenblit P D. Extreme Atherosclerotic Cardiovascular Disease (ASCVD) Risk Recognition [J/OL]. Current Diabetes Reports, 2019,19(8):61.
[18] Folsom A R, Kronmal R A, Detrano R C,et al. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence:the Multi-Ethnic Study of Atherosclerosis (MESA)[J/OL]. Archives of Internal Medicine,2008,168 (12):1333-1339.
[19] Barter P, Genest J.HDL cholesterol and ASCVD risk stratification: A debate[J/OL]. Atherosclerosis,2019,283:7-12.
[20] Hoogeveen R C, Ballantyne C M. Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a),and Inflammation[J/OL]. Clinical Chemistry,2021,67(1):143-153.
[21] Sandesara P B, Virani S S, Fazio S, et al. The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk[J/OL]. Endocrine Reviews, 2019, 40(2):537-557.
[22] Liu J, Hong Y, D' Agostino RB Sr, et al. Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study[J]. JAMA, 2004, 291(21): 2591-2599.
[23] Wu Y, Liu X, Li X, et al. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese adults[J]. Circulation, 2006, 114(21): 2217-2225. DOI: 10.1161/ CIRCULATIONAHA.105.607499.
[24] Yang X, Li J, Hu D, et al. Predicting the 10-year risks of atherosclerotic cardiovascular disease in Chinese population: The China-PAR Project (prediction for ASCVD risk in China) [J]. Circulation, 2016, 134(19): 1430-1440.
[25] Kaasenbrood L, Boekholdt SM, van der Graaf Y, et al. Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population[J]. Circulation, 2016, 134(19): 1419-1429.